

Rajat Kumar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4687196/publications.pdf>

Version: 2024-02-01

48
papers

476
citations

933447
10
h-index

752698
20
g-index

48
all docs

48
docs citations

48
times ranked

697
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an <scp>MDS</scp>â€<scp>CAN</scp> prospective study. British Journal of Haematology, 2016, 174, 88-101. | 2.5 | 78 |
| 2 | Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies. Biology of Blood and Marrow Transplantation, 2018, 24, 2259-2264. | 2.0 | 66 |
| 3 | Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD. Bone Marrow Transplantation, 2020, 55, 1773-1783. | 2.4 | 35 |
| 4 | Low rates of acute and chronic GVHD with ATG and PTCy in matched and mismatched unrelated donor peripheral blood stem cell transplants. European Journal of Haematology, 2019, 102, 486-493. | 2.2 | 32 |
| 5 | Pilot prospective study of Frailty and Functionality in routine clinical assessment in allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 60-69. | 2.4 | 26 |
| 6 | COVID-19 Testing in Patients with Cancer: Does One Size Fit All?. Clinical Cancer Research, 2020, 26, 4737-4742. | 7.0 | 23 |
| 7 | Reduced intensity allogeneic stem cell transplant with anti-thymocyte globulin and post-transplant cyclophosphamide in acute myeloid leukemia. European Journal of Haematology, 2019, 103, 510-518. | 2.2 | 19 |
| 8 | Safety and Efficacy of Haploidentical Peripheral Blood Stem Cell Transplantation for Myeloid Malignancies Using Post-transplantation Cyclophosphamide and Anti-thymocyte Globulin as Graft-versus-Host Disease Prophylaxis. Clinical Hematology International, 2019, 1, 105-113. | 1.7 | 18 |
| 9 | Clinical prevalence and outcome of cardiovascular events in the first 100 days postallogeneic hematopoietic stem cell transplant. European Journal of Haematology, 2021, 106, 32-39. | 2.2 | 16 |
| 10 | Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infections. Leukemia and Lymphoma, 2021, 62, 3373-3383. | 1.3 | 12 |
| 11 | Experience Using Anti-Thymocyte Globulin With Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Peripheral Blood Haploidentical Stem Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 428.e1-428.e9. | 1.2 | 11 |
| 12 | Bloodstream Infections and Outcomes Following Allogeneic Hematopoietic Cell Transplantation: A Single-Center Study. Transplantation and Cellular Therapy, 2022, 28, 50.e1-50.e8. | 1.2 | 11 |
| 13 | Impact of central nervous system involvement in AML on outcomes after allotransplant and utility of pretransplant cerebrospinal fluid assessment. European Journal of Haematology, 2019, 103, 483-490. | 2.2 | 10 |
| 14 | Transitioning to a New Normal in the Post-COVID Era. Current Oncology Reports, 2020, 22, 73. | 4.0 | 10 |
| 15 | Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Bone Marrow Transplantation, 2021, 56, 1908-1918. | 2.4 | 10 |
| 16 | Reduced-intensity conditioning allogeneic transplant with dual T-cell depletion in myelofibrosis. European Journal of Haematology, 2019, 103, 597-606. | 2.2 | 9 |
| 17 | High incidence but low mortality of EBV-reactivation and PTLN after alloHCT using ATG and PTCy for GVHD prophylaxis. Leukemia and Lymphoma, 2020, 61, 3198-3208. | 1.3 | 9 |
| 18 | Impact of CD34+ cell dose on reduced intensity conditioning regimen haploidentical hematopoietic stem cell transplantation. European Journal of Haematology, 2020, 104, 36-45. | 2.2 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Eltrombopag: Role in Cytopenias Following Hematopoietic Stem Cell Transplantation. Indian Journal of Hematology and Blood Transfusion, 2020, 36, 238-245. | 0.6 | 6 |
| 20 | Less Is More: Superior Graft-versus-Host Disease-Free/Relapse-Free Survival with Reduced-Intensity Conditioning and Dual T Cell Depletion in Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation, 2020, 26, 1511-1519. | 2.0 | 6 |
| 21 | Improving Safety and Outcomes After Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience. Transplantation and Cellular Therapy, 2022, 28, 265.e1-265.e9. | 1.2 | 6 |
| 22 | Allogeneic stem cell transplant in myelodysplastic syndrome—factors impacting survival. European Journal of Haematology, 2020, 104, 116-124. | 2.2 | 5 |
| 23 | Outcomes of therapy-related acute lymphoblastic leukemia in adults after allogeneic stem cell transplantation. European Journal of Haematology, 2020, 105, 24-29. | 2.2 | 5 |
| 24 | Inferior outcomes with reduced intensity conditioning followed by allogeneic hematopoietic cell transplantation in fit individuals with acute lymphoblastic leukemia: a Canadian single-center study and a comparison to registry data. Leukemia and Lymphoma, 2021, 62, 2193-2201. | 1.3 | 5 |
| 25 | Efficacy and cost analysis of eltrombopag in thrombocytopenia and poor graft function post allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 2471-2476. | 2.4 | 5 |
| 26 | Association of Factors Influencing Selection of Upfront Hematopoietic Cell Transplantation versus Nontransplantation Therapies in Myelofibrosis. Transplantation and Cellular Therapy, 2021, 27, 600.e1-600.e8. | 1.2 | 5 |
| 27 | Bilateral adrenal hemorrhage as a manifestation of extramedullary hematopoiesis in a patient with primary myelofibrosis. Annals of Hematology, 2018, 97, 2011-2012. | 1.8 | 3 |
| 28 | Impressive Graft-versus-Host Disease-Free, Relapse-Free Survival in Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-Intensity Conditioning and a Combination of Antithymocyte Globulin and Post-Transplantation Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2019, 25, e352-e353. | 2.0 | 3 |
| 29 | Predictors of outcomes of therapy-related acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Hematology/ Oncology and Stem Cell Therapy, 2021, , . | 0.9 | 3 |
| 30 | Epstein-Barr virus associated post-transplant lymphoproliferative disorder mimicking acute graft versus host disease. European Journal of Haematology, 2019, 103, 519-522. | 2.2 | 2 |
| 31 | Graft-versus-Host Disease—Free Relapse-Free Survival Definition for Patients with Nonmalignant Hematologic Disorders. Biology of Blood and Marrow Transplantation, 2020, 26, 428. | 2.0 | 2 |
| 32 | Impact of Covid-19 on Hematological Practice: Challenges and Opportunities. Indian Journal of Hematology and Blood Transfusion, 2020, 36, 603-604. | 0.6 | 2 |
| 33 | Combination of FLT3-ITD Allelic Ratio, NPM1 Mutation, and Immunophenotypic Markers to Modulate Outcome Prediction in Patients with Normal Karyotype Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1995-2000. | 2.0 | 2 |
| 34 | Prolactin, a potential biomarker for chronic GVHD activity. European Journal of Haematology, 2021, 106, 158-164. | 2.2 | 2 |
| 35 | Moderate-severe grade of chronic graft versus host disease and younger age (less than 45 years old) are risk factors for avascular necrosis in adult patients undergoing allogeneic hematopoietic cell transplantation. Annals of Hematology, 2021, 100, 1311-1319. | 1.8 | 2 |
| 36 | Effect of pre-transplant JAK1/2 inhibitors and CD34 dose on transplant outcomes in myelofibrosis. European Journal of Haematology, 2021, 107, 517-528. | 2.2 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Allogeneic hematopoietic stem cell transplantation in patients with therapy-related hematologic malignancies developing after multiple myeloma. <i>European Journal of Haematology</i> , 2022, 108, 430-436. | 2.2 | 2 |
| 38 | The 17-gene stemness score associates with relapse risk and long-term outcomes following allogeneic haematopoietic cell transplantation in acute myeloid leukaemia. <i>EJHaem</i> , 2022, 3, 873-884. | 1.0 | 2 |
| 39 | Relationship between certain HLA alleles and the risk of cytomegalovirus reactivation following allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2022, 24, . | 1.7 | 2 |
| 40 | Effect of donor age and kinship on outcomes in haplo-identical stem cell transplantation may be modulated by GVHD prophylaxis strategies. <i>Bone Marrow Transplantation</i> , 2021, 56, 689-691. | 2.4 | 1 |
| 41 | Refined hepatic grading system in chronic graft-versus-host disease improves prognostic risk stratification of long-term outcomes. <i>European Journal of Haematology</i> , 2021, 106, 508-519. | 2.2 | 1 |
| 42 | Largest Single Center Experience Using Dual T-Cell Depletion with ATG and Ptcy for Gvhd Prophylaxis in Peripheral Blood RIC Allo-HSCT. <i>Blood</i> , 2019, 134, 3344-3344. | 1.4 | 0 |
| 43 | The 17-Gene Leukemic Stemness Score Can Predict Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 3299-3299. | 1.4 | 0 |
| 44 | Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning. <i>Blood</i> , 2019, 134, 4590-4590. | 1.4 | 0 |
| 45 | No Impact of Donor's Age-Related Clonal Hematopoiesis (ARCH) Observed on Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: Result from Bar-Coded Error Corrected Sequencing in 33 Gene Mutations on 372 Pairs of Donor and Recipient. <i>Blood</i> , 2019, 134, 4514-4514. | 1.4 | 0 |
| 46 | Update of Multicenter, Retrospective Evaluation of Overall Response and Failure Free Survival Following Ruxolitinib Therapy for Heavily Pre-Treated Chronic Gvhd Patients with Steroid-Failure: A Proposal of Risk Score Model for Failure-Free Survival. <i>Blood</i> , 2021, 138, 3905-3905. | 1.4 | 0 |
| 47 | Outcomes of patients diagnosed with chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation: Results from a tertiary care center. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , . | 0.9 | 0 |
| 48 | Allogeneic Hematopoietic Stem Cell Transplant Versus Gene Therapy in Sickle Cell Disease: Updated Results from a Systematic Review. <i>Blood</i> , 2020, 136, 11-12. | 1.4 | 0 |